Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Estimated Market Size of the Choroidal Neovascularization Market In 2029?
In the recent past, the market size for choroidal neovascularization has seen robust growth. An expected increase from $3.37 billion in 2024 to $3.61 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%, is predicted. The historical period’s advancement can be credited to the increasing spread of diseases linked to inactive lifestyles, a growing case of age-related macular degeneration, an increase in retinal disease cases, an aging population, escalating costs for eye care, and the expansion of education and screening programs.
The market size for choroidal neovascularization is projected to see robust growth over the coming years, increasing to $5.64 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is credited to heightened patient awareness, amplified adoption of optical coherence tomography angiography, rising demand for minimally invasive procedures, agreeable reimbursement policies, and an expanding elderly populace. Key trends forecasted in this period include the advent of intravitreal anti-vascular endothelial (VEGF) treatments, innovative gene therapies and approaches, the implementation of telemedicine, the creation of combination therapies, and personalized treatment plans.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Choroidal Neovascularization Market?
The growth of the choroidal neovascularization (CNV) market is anticipated to be fueled by the rising instances of age-related macular degeneration (AMD). AMD, an eye disease often seen in the elderly, gradually impairs the macula, resulting in the loss of central vision. This increase in AMD cases can be attributed to factors such as an aging population, increased lifespan, changes in lifestyle, hereditary factors, and heightened exposure to environmental hazards. CNV aids in managing AMD by contributing to the onset of the wet form of AMD, which is characterized by the growth of abnormal blood vessels beneath the retina, causing declining vision that necessitates advanced treatments like anti-VEGF therapy. Such treatments help manage CNV and delay the progression of AMD, thereby preserving central vision in those affected. To illustrate, the National Institutes of Health, a government agency based in the United States, has estimated that by 2040, the number of AMD cases could hit 300 million, and by 2050, as many as 5.4 million Americans could be affected. Therefore, the escalating rate of AMD is stimulating the growth of the CNV market.
Which Key Market Segments Comprise the Choroidal Neovascularization Market and Drive Its Revenue Growth?
The choroidal neovascularization market covered in this report is segmented –
1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp
Which Areas Are Leading Regions in the Choroidal Neovascularization Market Expansion Across the Globe?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theChoroidal Neovascularization Market Direction?
Leading corporations in the choroidal neovascularization market are honing in on the development of innovative treatments such as photodynamic therapy, with the aim of providing eye care experts with precise and effective treatment alternatives that enhance patient results and treatment provision. Photodynamic therapy (PDT) is a medicinal procedure that utilizes light to activate a photosensitizing agent, which in turn targets and eradicates unusual or cancerous cells. As an illustration, Bausch & Lomb, a healthcare firm based in Canada, and Modulight, a biomedical company in Finland, proclaimed in February 2023 the Food and Drug Administration’s (a US-based government agency) endorsement of the ML6710i photodynamic laser. Its approval paves the way for its utilization with Bausch + Lomb’s VISUDYNE therapy, which has been created to counter choroidal neovascularization, an issue stemming from age-related macular degeneration (AMD). This advanced, portable ophthalmic laser devises a strategic plan for managing abnormal blood vessels in the eye, thereby halting further disease development and safeguarding vision.
View the full report here:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report
How Is the Choroidal Neovascularization Market Conceptually Defined?
Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage the retinal tissues, leading to vision distortion or loss.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model